Angina Pectoris
📧 Sign up to get email alerts when something new happens for Angina Pectoris.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-06-25FDA Approved: NICARDIPINE HYDROCHLORIDE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved NICARDIPINE HYDROCHLORIDE as a generic product under an Original Application (ANDA) from Zydus Pharmaceuticals USA Inc. This co…
-
CLINICAL_TRIALS trial_result · 2025-06-11Clinical Trial Update: Chronic Total Coronary Occlusion Treatment Results 6 Years After Bioresorbable Scaffold Implantation [NA]
Long-term follow-up of chronic total occlusion treatment with a bioresorbable scaffold shows outcomes 6 years after implantation.
-
FDA approval · 2025-06-11FDA Approved: METOPROLOL TARTRATE — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for metoprolol tartrate (Hospira, Inc.), a generic beta-blocker, confirming continued approval of th…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Evaluation of Patients With Non-obstructive Coronary Arteries
Stanford University is conducting a trial evaluating patients with non-obstructive coronary arteries who present chest pain and ischemia; th…
-
CLINICAL_TRIALS research · 2025-06-03Clinical Trial Update: Development of a Novel Risk Prediction Tool for Emergency Department Patients Symptoms of Coronary Artery Disease
A clinical study is developing a novel risk prediction tool for emergency department patients with symptoms of coronary artery disease; the …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-05-21Clinical Trial Update: Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis [NA]
A clinical trial update describes testing sirolimus with corticosteroid therapy to address rapid recurrences of coronary unexplained in-sten…
-
FDA approval · 2025-05-09FDA Approved: NICARDIPINE HYDROCHLORIDE — Supplemental Application (Lifestar Pharma LLC)
FDA approved a supplemental application for nicardipine hydrochloride from Lifestar Pharma LLC, indicating a change under an approved ANDA.
-
FDA approval · 2025-05-06FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for diltiazem hydrochloride from Mylan Pharmaceuticals Inc., enabling continued marketing of the…
-
CLINICAL_TRIALS research · 2025-04-27Clinical Trial Update: A Multi-center, Real-World Clinical Trial of caIMR on Two Specific Kinds of Patients.
Clinical trial update for a multi-center real-world study of caIMR in patients with coronary microvascular dysfunction and angina. The study…
-
CLINICAL_TRIALS research · 2025-04-25Clinical Trial Update: Myocardial Perfusion Quantification With SPECT Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary CTA [NA]
This clinical trial update reports a recruiting study comparing quantitative myocardial perfusion imaging by SPECT with a multi-pinhole coll…
-
CLINICAL_TRIALS trial_result · 2025-04-23Clinical Trial Update: PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX) [NA]
This clinical trial PRECISION-COMPLEX is evaluating precision percutaneous coronary intervention for complex coronary lesions. It is current…
-
FDA approval · 2025-04-17FDA Approved: NICARDIPINE HYDROCHLORIDE — Supplemental Application (Epic Pharma, LLC)
The FDA approved a supplemental application for Nicardipine hydrochloride from Epic Pharma, LLC, under the ANDA process. This represents a s…
-
FDA approval · 2025-04-16FDA Approved: DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE — Supplemental Application (Oceanside Pharmaceuticals)
The FDA approved Oceanside Pharmaceuticals' supplemental NDA for the extended-release form of diltiazem hydrochloride.
-
FDA approval · 2025-04-16FDA Approved: CARDIZEM LA — Supplemental Application (Bausch Health US LLC)
The FDA approved a supplemental application for Cardizem LA (diltiazem hydrochloride extended-release) submitted by Bausch Health US LLC.
-
FDA label_change · 2025-04-16FDA Approved: CARDIZEM CD — Supplemental Application (Bausch Health US LLC)
FDA approves a supplemental application for Cardizem CD (diltiazem hydrochloride) by Bausch Health US LLC.
-
FDA approval · 2025-04-16FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved a supplemental application for diltiazem hydrochloride by Oceanside Pharmaceuticals.
-
FDA approval · 2025-04-15FDA Approved: NITROGLYCERIN — Original Application (Encube Ethicals, Inc.)
FDA approves Encube Ethicals, Inc.'s nitroglycerin product under an Original Application (ANDA). This expands access to a generic nitroglyce…
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction. [NA]
A clinical trial update indicates that Coronary Sinus Reducer implantation is being evaluated for patients with ischemia and non-obstructed …
-
FDA approval · 2025-03-28FDA Approved: NICARDIPINE HYDROCHLORIDE — Supplemental Application (Cipla USA Inc.)
The FDA approved a supplemental application for nicardipine hydrochloride from Cipla USA Inc., indicating an update to this generic product'…
-
FDA approval · 2025-03-24FDA Approved: METOPROLOL TARTRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for metoprolol tartrate by Hikma Pharmaceuticals USA Inc. (ANDA 077761), updating the regulatory sta…
-
FDA approval · 2025-03-17FDA Approved: ATENOLOL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Atenolol from Teva Pharmaceuticals USA, Inc.
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: Diagnostic Accuracy Of Seismocardiography for Coronary Artery Disease [NA]
This completed clinical trial, sponsored by Heart Force Medical Inc., evaluated the diagnostic accuracy of seismocardiography for coronary a…
-
FDA approval · 2025-03-07FDA Approved: BISOPROLOL FUMARATE — Supplemental Application (TruPharma LLC)
FDA approved a supplemental application for Bisoprolol Fumarate from TruPharma LLC, validating the generic product under ANDA075643.
-
CLINICAL_TRIALS trial_result · 2025-02-25Clinical Trial Update: Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging [Phase 2]
Phase 2 trial evaluating the efficacy of medical therapy in women and men with angina and myocardial bridging; the study was terminated with…
-
FDA approval · 2025-02-21FDA Approved: DILTIAZEM HYDROCHLORIDE IN SODIUM CHLORIDE — Original Application (WG Critical Care, LLC)
FDA approved a new injectable diltiazem hydrochloride in sodium chloride under an original NDA from WG Critical Care, LLC. This parenteral f…